Series A · $93M · October 2026 · Biotech & pharma · North America
Estuary Biotherapeutics is a biotech focused on ADPKD (autosomal dominant polycystic kidney disease).
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-20 | Series A | $93M | — | news.google.com |
| 2026-10-19 | Series A | $93M | RA Capital (lead) | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-29.
StimCardio Medical is developing a non-invasive wearable neuromodulation platform combining continuous physiological sensing with personalized therapy, starting with atrial…
Coherence designs therapeutic neurotechnology to manage cancer from inside the body; its flagship SOMA is a brain-computer interface with a wireless coin-sized implant, an…
Single-cell analysis and isolation technology (Xdrop instrument, consumables and digital tools) with applications in immunotherapy, antibody discovery, screening and genomics.
Atlas Bio runs in silico clinical trials in immunology using a foundation AI model of human biology to predict and compare patient responses across treatments and indications.
In silico studies for implantable devices: Virtual Chimera technology generates fully synthetic virtual patients from anonymised clinical imaging, and physics-based simulation…
Lab-automation platform that miniaturizes experiments to nanoliter volumes, turning precious patient samples into high-dimensional datasets for genomic discovery and personalized…
